The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Patients With Advanced Malignancies
Open accessAbstract
Purpose: We conducted the first phase 0 clinical trial in oncology of a therapeutic agent under the Exploratory Investigational New Drug Guidance of the US Food and Drug Administration. It was a first-in-human study of the poly (ADP-ribose) polymerase (PARP) inhibitor ABT-888 in patients with advanced malignancies. Patients and Methods: ABT-888 was administered as a single oral dose of 10, 25, or 50 mg to determine the dose range and time course over which ABT-888 inhibits PARP activity in tumor samples and peripheral blood mononuclear cells, and to evaluate ABT-888 pharmacokinetics. Blood samples and tumor biopsies were obtained pre- and postdrug administration for evaluation of PARP activity and pharmacokinetics. A novel statistical approach was developed and utilized to study pharmacodynamic modulation as the primary end point for trials of limited sample size. Results: Thirteen patients with advanced malignancies received the study drug; nine patients underwent paired tumor biopsies. ABT-888 demonstrated good oral bioavailability and was well tolerated. Statistically significant inhibition of poly (ADP-ribose) levels was observed in tumor biopsies and peripheral blood mononuclear cells at the 25-mg and 50-mg dose levels. Conclusion: Within 5 months of study activation, we obtained pivotal biochemical and pharmacokinetic data that have guided the design of subsequent phase I trials of ABT-888 in combination with DNA-damaging agents. In addition to accelerating the development of ABT-888, the rapid conclusion of this trial demonstrates the feasibility of conducting proof-of-principle phase 0 trials as part of an alternative paradigm for early drug development in oncology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Poly(ADP-ribose): novel functions for an old molecule
Schreiber, V., Dantzer, F., Ame, J.-C., & de Murcia, G. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1963 · Cited by 1,915
Amé, J., Spenlehauer, C., & de Murcia, G. (2004) · BioEssays · doi:10.1002/bies.20085 · Cited by 1,459
Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells
de Murcia, J. M., Niedergang, C., Trucco, C., Ricoul, M., Dutrillaux, B., Mark, M., Oliver, F. J., Masson, M., Dierich, A., LeMeur, M., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.14.7303 · Cited by 1,056
Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors
Jagtap, P., & Szabó, C. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1718 · Cited by 896
Donawho, C. K., Luo, Y., Luo, Y., Penning, T. D., Bauch, J. L., Bouska, J. J., Bontcheva-Diaz, V. D., Cox, B. F., DeWeese, T. L., Dillehay, L. E., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-3039 · Cited by 773
Self-citationCurrent Development of Clinical Inhibitors of Poly(ADP-Ribose) Polymerase in Oncology
Ratnam, K., & Low, J. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2260 · Cited by 286
Self-citationAlbert, J. M., Cao, C., Kim, K. W., Willey, C. D., Geng, L., Xiao, D., Wang, H., Sandler, A., Johnson, D. H., Colevas, A. D., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2872 · Cited by 266
Self-citationCompressing drug development timelines in oncology using phase '0' trials
Kummar, S., Kinders, R., Rubinstein, L., Parchment, R. E., Murgo, A. J., Collins, J., Pickeral, O., Low, J., Steinberg, S. M., Gutierrez, M., et al. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2066 · Cited by 213
Self-citationChemopotentiation by PARP inhibitors in cancer therapy
Tentori, L., & Graziani, G. (2005) · Pharmacological Research · doi:10.1016/j.phrs.2005.02.010 · Cited by 192
The response of Parp knockout mice against DNA damaging agents
Masutani, M., Nozaki, T., Nakamoto, K., Nakagama, H., Suzuki, H. I., Kusuoka, O., Tsutsumi, M., & Sugimura, T. (2000) · Mutation Research/Reviews in Mutation Research · doi:10.1016/s1383-5742(00)00033-8 · Cited by 130
Inhibition of poly(ADP-ribose) polymerase in cancer
Plummer, E. R. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.02.004 · Cited by 106
Designing Phase 0 Cancer Clinical Trials
Murgo, A. J., Kummar, S., Rubinstein, L., Gutierrez, M. E., Collins, J. M., Kinders, R. J., Parchment, R. E., Ji, J. J., Steinberg, S. M., Yang, S. X., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4560 · Cited by 104
Self-citationDowlati, A., Haaga, J. R., Remick, S. C., Spiro, T. P., Gerson, S. L., Liu, L., Berger, S. J., Berger, N. A., & Willson, J. K. V. (2001) · PubMed · Cited by 91
Phase 0 Clinical Trials in Cancer Drug Development: From FDA Guidance to Clinical Practice
Kinders, R. J., Parchment, R. E., Ji, J. H., Kummar, S., Murgo, A. J., Gutierrez, M. E., Collins, J. M., Rubinstein, L., Pickeral, O. K., Steinberg, S. M., et al. (2007) · Molecular Interventions · doi:10.1124/mi.7.6.9 · Cited by 83
Self-citationKinders, R. J., Hollingshead, M. G., Khin, S. A., Rubinstein, L., Tomaszewski, J. E., Doroshow, J. H., & Parchment, R. E. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0214 · Cited by 82
Self-citationShiobara, M., Miyazaki, M., Ito, H., Togawa, A., Nakajima, N., Nomura, F., Morinaga, N., & Noda, M. (2001) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.2001.02378.x · Cited by 81
Enhanced expression of poly(ADP‐ribose) synthetase gene in malignant lymphoma
Tomoda, T., Kurashige, T., Moriki, T., Yamamoto, H., Fujimoto, S., & Taniguchi, T. (1991) · American Journal of Hematology · doi:10.1002/ajh.2830370402 · Cited by 79
Regulation of Chromatin Structure and Gene Activity by Poly(ADP-Ribose) Polymerases
Tulin, A. V., Chinenov, Y. V., & Spradling, A. C. (2003) · Current topics in developmental biology/Current Topics in Developmental Biology · doi:10.1016/s0070-2153(03)01007-x · Cited by 57
Helft, P. R., & Daugherty, C. K. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.7125 · Cited by 57
Phillips, L. R., Hill, K. D., & Majerová, E. (2008) · Journal of Liquid Chromatography & Related Technologies · doi:10.1080/10826070802603351 · Cited by 10
Self-citation
Cited by
Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib
Murai, J., Huang, S.-Y. N., Renaud, A., Zhang, Y., Ji, J., Takeda, S., Morris, J., Teicher, B., Doroshow, J. H., & Pommier, Y. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0803 · Cited by 756
Self-citationDelivering affordable cancer care in high-income countries
Sullivan, R., Peppercorn, J., Sikora, K., Zalcberg, J., Meropol, N. J., Amir, E., Khayat, D., Boyle, P., Autier, P., Tannock, I. F., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70141-3 · Cited by 718
PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance
Rose, M., Burgess, J. T., O’Byrne, K., Richard, D. J., & Bolderson, E. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.564601 · Cited by 719
Dual Roles of PARP-1 Promote Cancer Growth and Progression
Schiewer, M. J., Goodwin, J. F., Han, S., Brenner, J. C., Augello, M. A., Dean, J. L., Liu, F., Planck, J. L., Ravindranathan, P., Chinnaiyan, A. M., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0120 · Cited by 442
Plummer, R., Jones, C., Middleton, M., Wilson, R., Evans, J., Olsen, A., Curtin, N., Boddy, A., McHugh, P., Newell, D., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1223 · Cited by 383
Metadata
- Authors
- Kummar, S., Kinders, R., Gutierrez, M. E., Rubinstein, L., Parchment, R. E., Phillips, L. R., Ji, J., Monks, A., Low, J. A., Chen, A., Murgo, A. J., Collins, J., Steinberg, S. M., Eliopoulos, H., Giranda, V. L., Gordon, G., Helman, L., Wiltrout, R., Tomaszewski, J. E., & Doroshow, J. H.
- Venue
- Journal of Clinical Oncology
- Published
- 2009-06-01
- Volume
- 27
- Issue
- 16
- Pages
- 2705-2711
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2118682535
- Cited by
- 326
- References
- 21
- FWCI
- 15.66
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.